http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-078045-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c76fa813ca37f752642817cd07c3d437
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0a910d33c239980f3a705e312c5bad6a
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D239-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D239-49
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-12
filingDate 2010-05-21-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c970480975a0721bf5b99db446a5f1a6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7f8c0038880ff84df7230f0ccb00a8b5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4d79035fc7d61f4d3b097a1fe2e13c7d
publicationDate 2011-10-12-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber AR-078045-A1
titleOfInvention PIRIMIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM AND THEIR USE IN THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OF CANCER
abstract Pharmaceutical compositions containing them and their use in the treatment of diseases, for example, cancer. Claim 1: A compound of the Formula (1), or a pharmaceutically acceptable salt thereof characterized in that: X represents -CH2-, -NR8-, -O- or -S (O) n-; R 1 represents C 1-6 alkyl, C 2-6 alkoxy, C 1-6 alkoxy, C 1-6 alkyl, C 1-6 hydroxyalkyl, C 1-6 hydroxyalkoxy or C 1-6 hydroxyalkoxyC 1-6 alkyl; R2 represents hydrogen, C1-6 alkyl or phenyl wherein said phenyl is optionally substituted by 1, 2 or 3 substituents selected from R6; R3 represents C1-6 alkyl, C1-6 alkoxy or -S-C1-6 alkyl; R4 represents hydrogen, halogen, C1-6 alkyl or C1-6 alkoxy; L1 represents a direct link, - (CR9R10) m-, -CH = CH- (CR9R10) q-, -C ::: C- (CR9R10) q-, -O- (CR9R10) q-, -C (O ) -O- (CR9R10) q- or -O- (CH2) qNR8- (CH2) q-; R5 represents methyl, hydroxy, -NR11R12, C3-6 cycloalkyl, phenyl or a monocyclic, or 4, 5, 6 or 7-membered heterocyclic ring comprising 1, 2 or 3 heteroatoms independently selected from O, N or S wherein said phenyl and heterocyclic rings are optionally substituted by 1, 2 or 3 substituents selected from R7; R6 represents C1-6 alkyl, C1-6 fluoroalkyl, C1-6 alkoxy, hydroxy, halogen, cyano, -S (O) n-C1-6 alkyl or -CH2-C (O) -O-C1-6 alkyl; R7 represents C1-6 alkyl, C1-6 alkoxy, C1-6 alkoxyC1-6 alkyl, hydroxy, hydroxyC1-6 alkyl, or - (CH2) q-NR11R12; R8 represents hydrogen or C1-6 alkyl; R9 and R10, identically or differently in each case, represents hydrogen or methyl; R11 and R12 independently represent hydrogen, C1-4alkyl or C1-4alkoxyC2-4alkyl; m represents 1, 2, 3, 4, 5 or 6; n represents 0, 1 or 2; and q represents, 0, 1, 2, 3, 4, 5 or 6; with the proviso that the compound of Formula (1) is not: [3- (2-amino-4-methyl-6-pentylamino-pyrimidin-5-ylmethyl)] -benzoic acid ethyl ester; Methyl 4 - ((2-amino-4-methyl-6- (pentylamino) pyrimidin-5-yl) methyl) -3-methoxybenzoate; or 4 - ((2-amino-4-methyl-6- (pentylamino) pyrimidin-5-iI) methyl) -3-fluorobenzoate.
priorityDate 2009-05-21-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID66819205
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID411412122
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458393636
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID421558136
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID49806175
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID456089904
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458392451
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458397310
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID454973655
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID425193155
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID783
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458394811

Total number of triples: 45.